Federal Grant Supports Cortex Stroke Research

Cortex Pharmaceuticals Inc., which is developing therapies for neurological and psychiatric disorders, said Wednesday that the National Institutes of Health has agreed to fund continued research on a therapy for strokes.

The Irvine neuroscience company said in a press release that it expects the grant to cover three years and provide total funding of $1,074,157. The principal investigator is Gary A. Rogers, a Cortex senior vice president.

The grant under a Phase II Small Business Innovative Research program follows funding previously awarded under the program.